T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Adoptive T Cell Therapy Applications

A universal solution emerges: Anti-linker antibodies simplify CAR-T detection and development

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid tumors.

From Sino Biological Inc. 13 Sep 2025

New AI model can identify treatments that reverse disease states in cells

In a move that could reshape drug discovery, researchers at Harvard Medical School have designed an artificial intelligence model capable of identifying treatments that reverse disease states in cells.

10 Sep 2025

Tarlatamab and anti-PD-L1 therapy combination demonstrates manageable safety profile in first-line ES-SCLC

Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

8 Sep 2025

Plant-derived carotenoid found to boost immune response against cancer

In a new study, researchers from the University of Chicago discovered that zeaxanthin, a plant-derived carotenoid best known for protecting vision, may also act as an immune-boosting compound by strengthening the cancer-fighting activity of immune cells.

2 Sep 2025

Scientists discover molecular brake that limits T cell attack on tumors

In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to attack tumors.

1 Sep 2025

Special robot hunts for the perfect cancer warriors

Cancer patients can regain full health with immunotherapy. Now researchers are hunting for the perfect immune cell with the help of a very special robot.

18 Aug 2025

Electrophysiology-based strategies enhance cancer immunotherapy

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy.

17 Aug 2025

Plasma proteomics study unlocks predictive biomarkers for TNBC immunotherapy

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option.

17 Aug 2025

Respiratory viruses awaken dormant breast cancer cells and raise relapse risk

Respiratory viruses such as influenza and COVID-19 can reactivate dormant breast cancer cells in the lungs, raising the risk of metastasis. The process is driven by IL-6–induced cell changes and immune suppression, with the highest recurrence risk soon after infection.

14 Aug 2025

Novel vaccine shows promise against KRAS-driven pancreatic and colorectal cancers

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies, according to a study led in part by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

12 Aug 2025

Gut microbiota and short chain fatty acids influence bone health in postmenopausal osteoporosis

Postmenopausal osteoporosis (PMOP) is framed as a systemic bone disease driven by estrogen withdrawal, but emerging evidence positions gut dysbiosis and its fermentation products—short-chain fatty acids (SCFAs)—as equally influential regulators of skeletal fate.

6 Aug 2025

Targeting lactate metabolism offers new avenues for cancer treatment

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of tumor-immune crosstalk.

5 Aug 2025

AI-designed protein activates Notch signaling pathway to boost T-cell production

A new paper published today in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.

1 Aug 2025

Two-drug combo shows durable benefit in advanced kidney cancer

A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

1 Aug 2025

Novel insights from lymphoid structures: Lessons from colorectal cancer research

Discover how lymphoid structures and germinal centers provide powerful prognostic insights into colorectal cancer.

From TissueGnostics 31 Jul 2025

T cell senescence shapes cancer prognosis and immunotherapy response

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by tumor-associated antigens, metabolic pathway alterations, activation of chronic inflammatory responses, proliferation of immunosuppressive cells, and T cell damage caused by tumor radiotherapy and chemotherapy.

31 Jul 2025

Cancer-associated fibroblasts exhibit paradoxical effects on immunotherapy

Cancer-associated fibroblasts (CAFs) – critical but enigmatic players in tumors – exhibit "paradoxical" effects on immunotherapy, according to a new review in Clinical and Translational Discovery.

31 Jul 2025

Immunocompromised people are susceptible to skin cancer caused directly by beta-HPV

Researchers at the National Institutes of Health (NIH) have shown for the first time that a type of human papillomavirus (HPV) commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma (cSCC) when certain immune cells malfunction.

30 Jul 2025

Understanding immune drift in biologic therapy for inflammatory skin diseases

Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4).

28 Jul 2025

VCU Massey pioneers clinical trial of novel GGT-1 inhibitor PTX-100

VCU Massey Comprehensive Cancer Center is the first site in the United States to be activated in a global Phase 2a clinical trial evaluating PTX-100 (AKA GGTI-2418), a first-in-class small molecule inhibitor of geranylgeranyl transferase-1 (GGT-1), for the treatment of cutaneous T-cell lymphoma (CTCL), a rare and often treatment-resistant T-cell lymphoma.

26 Jul 2025